Key Takeaways
- • Artivest released a 16-page whitepaper titled "Five Things Every Cannabis Investor Needs to Know" authored by Chief Investment Officer Matt Osborne, addressing the expanding legal cannabis market following November 6th voter approval in Michigan, Missouri, and Utah, bringing total legalized states to 33.
- • Legal cannabis retail sales reached $9.5 billion in 2017, with the U.S. accounting for $8.5 billion (90% of global revenue), positioning America as the world's largest marijuana market.
- • Consumer equity research analysts forecast legal cannabis retail sales will reach $75 billion by 2030, while cannabis-derived pharmaceuticals and nutraceuticals are projected to exceed $100 billion in sales by 2025.
- • Public support for marijuana legalization has reached 64% according to Gallup polling—the highest level in nearly 50 years—driven by exhaustion with anti-marijuana prosecution, growing acceptance, and cannabis positioning as an opioid epidemic alternative.
- • Artivest's whitepaper targets investment professionals and qualified investors, available for registration at cannabis.artivest.co, emphasizing careful evaluation of cannabis investment offerings with professional advisors.
Summary
Artivest, a New York and San Diego-based investment firm, published a comprehensive 16-page whitepaper on November 14, 2018, addressing the legal cannabis industry for institutional and retail investors. The timing reflects momentum from recent voter initiatives: on November 6, 2018, American voters approved cannabis legalization measures in Michigan, Missouri, and Utah, expanding the total number of legalized states to 33 for either recreational or medical use.
The whitepaper, authored by Artivest Chief Investment Officer Matt Osborne, provides investment professionals and accredited investors with foundational analysis of the emerging cannabis sector. Osborne framed the industry's investment case around three primary drivers: growing public acceptance of cannabis, waning enforcement of anti-marijuana laws, and interest in cannabis as a therapeutic alternative to the opioid epidemic. The firm emphasizes that individual investors must carefully evaluate cannabis investment offerings in consultation with their advisors.
The research presented striking market data points. Legal cannabis retail sales reached $9.5 billion in 2017, with the United States generating $8.5 billion, representing 90% of global cannabis revenue and establishing America as the world's largest marijuana market. Consumer equity research analysts forecast that legal cannabis retail sales will expand to $75 billion by 2030. Beyond retail, cannabis-derived pharmaceuticals and nutraceuticals are projected to surpass $100 billion in sales by 2025, according to healthcare equity analysts. Public sentiment supports continued expansion: Gallup polling shows 64% of Americans now support marijuana legalization, marking the highest level recorded in nearly half a century.
Artivest invites investors and advisors to register online at cannabis.artivest.co to access the complete whitepaper, positioning institutional capital toward a newly legalized asset class with substantial growth projections and evolving regulatory frameworks across state jurisdictions.
The whitepaper, authored by Artivest Chief Investment Officer Matt Osborne, provides investment professionals and accredited investors with foundational analysis of the emerging cannabis sector. Osborne framed the industry's investment case around three primary drivers: growing public acceptance of cannabis, waning enforcement of anti-marijuana laws, and interest in cannabis as a therapeutic alternative to the opioid epidemic. The firm emphasizes that individual investors must carefully evaluate cannabis investment offerings in consultation with their advisors.
The research presented striking market data points. Legal cannabis retail sales reached $9.5 billion in 2017, with the United States generating $8.5 billion, representing 90% of global cannabis revenue and establishing America as the world's largest marijuana market. Consumer equity research analysts forecast that legal cannabis retail sales will expand to $75 billion by 2030. Beyond retail, cannabis-derived pharmaceuticals and nutraceuticals are projected to surpass $100 billion in sales by 2025, according to healthcare equity analysts. Public sentiment supports continued expansion: Gallup polling shows 64% of Americans now support marijuana legalization, marking the highest level recorded in nearly half a century.
Artivest invites investors and advisors to register online at cannabis.artivest.co to access the complete whitepaper, positioning institutional capital toward a newly legalized asset class with substantial growth projections and evolving regulatory frameworks across state jurisdictions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.